Short-course anti-TB therapy followed regression of reactivated focus

What the study found: A 69-year-old man with lung squamous cell carcinoma had reactivation of a previously stable, untreated pulmonary tuberculous focus after chemoimmunotherapy with tislelizumab. The reactivated lesion later regressed to its original baseline size even though he did not complete a full anti-tuberculosis course.
Why the authors say this matters: The authors suggest that a short course of anti-tuberculosis therapy aimed at lowering bacterial burden may be a viable way to manage immune checkpoint inhibitor-related tuberculosis reactivation and may allow continued use of immune checkpoint inhibitors.
What the researchers tested: This was a case report of one patient treated with paclitaxel, carboplatin, and tislelizumab. The tuberculous focus was identified as reactivated by next-generation sequencing, and the patient was followed after stopping anti-tuberculosis therapy early because of severe combined toxicity.
What worked and what didn't: The cancer mass regressed after four cycles of treatment. The tuberculous lesion reactivated, then regressed back to baseline after about two months of anti-tuberculosis therapy that was not completed; both lesions were stable at 10 months while tislelizumab maintenance continued.
What to keep in mind: This is a single case report, so it describes one patient's course rather than a general treatment rule. The abstract notes that management of immune checkpoint inhibitor-activated tuberculosis lacks consensus, and it does not provide a full anti-tuberculosis regimen or comparative evidence.

Key points

• A previously stable pulmonary tuberculous focus reactivated after tislelizumab-containing chemoimmunotherapy.
• Next-generation sequencing was used to confirm the reactivation.
• The patient stopped anti-tuberculosis therapy after about two months because of severe combined toxicity.
• Despite not completing full anti-TB treatment, the reactivated lesion regressed to its original baseline size.
• At 10 months, both the cancer lesion and the tuberculous lesion were stable while tislelizumab maintenance continued.